GLMD 6-K SEC Filing Analysis

Latest settled — T+20d

GLMD ▼ -20.00% at T+20d

LONG call ✗ call lost -20.00% · α vs SPY -27.57% · entry $0.7850 → $0.6280

Next anchor: T+60d in 21d

Last close $0.6120 (close Jun 12) · -22.04% from $0.7850 entry

Entry anchored
Apr 9, 08:40 AM ET
via Databento tick

T+1d

-5.61%

call -5.61% · α -5.54%

$0.7410

settled 2mo ago

T+5d

-5.86%

call -5.86% · α -9.05%

$0.7390

settled 2mo ago

T+20d

-20.00%

call -20.00% · α -27.57%

$0.6280

settled 6w ago

T+60d

—

call — · α —

—

in 21d

Price Chart

Loading chart...

Executive Summary

Galmed announced the development of a brain-penetrant formulation of its SCD1 inhibitor, Aramchol, in collaboration with Barcode Nanotech, enabling potential treatment of Parkinson's disease and other CNS disorders by crossing the blood-brain barrier. The advancement is based on proprietary nanoparticle technology and preliminary in-vitro data showing reduced alpha-synuclein aggregation.

Actionable Insight

Traders should monitor for upcoming regulatory feedback and initiation of clinical trials in H2 2026, which could serve as near-term catalysts. The expansion into CNS may re-rate the stock if larger market potential is recognized.

Key Facts

Galmed developed a new brain-penetrant formulation of Aramchol using lipid nanoparticles to cross the blood-brain barrier (BBB).
The formulation was co-developed with Barcode Nanotech using AI-driven in vivo screening of nanoparticle delivery systems.
In-vitro studies show Aramchol dose-dependently down-regulates alpha-synuclein (αSyn) aggregation, a hallmark of Parkinson’s disease and related synucleinopathies.
No current disease-modifying therapies exist for Parkinson’s, MSA, or DLB, creating significant unmet medical need.
Galmed plans to advance to a proof-of-concept Phase 1b/2 trial in PD patients in H2 2026, pending regulatory input.

Financial Impact

High strategic and valuation upside due to pipeline expansion into large, underserved CNS markets; no immediate revenue impact but increases probability of future commercial success.

pipeline valueR&D potentialmarket opportunity

Risk Factors

Clinical development risk: The new formulation has only in-vitro data; efficacy and safety in humans remain unproven.
Regulatory risk: Entry into CNS trials depends on regulatory acceptance of preclinical package.
Dilution risk: Galmed may need to raise capital to fund expanded CNS development.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001493152-26-015824
Document: form6-k.htm	0001493152-26-015824
Document: 0001493152-26-015824-index-headers.html	0001493152-26-015824
Document: 0001493152-26-015824-index.html	0001493152-26-015824
Document: 0001493152-26-015824.txt	0001493152-26-015824

6 reports for GLMD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for GLMD — sortable, filterable
	Type				Now
Jun 8, 2026 6d ago	6-K BULLISH ★ 7/10	$0.6838 awaiting T+1	awaiting T+1	—	$0.6120 (−10.50%)
Jun 2, 2026 12d ago	6-K NEUTRAL ★ 4/10	$0.6910 $0.6800	▼ −1.59%	▼ −0.90%	$0.6120 (−11.43%)
May 14, 2026 4w ago	6-K BULLISH ★ 7/10	$0.6590 $0.6000	▼ −8.95%	▼ −7.73%	$0.6120 (−7.13%)
May 6, 2026 5w ago	6-K NEUTRAL ★ 3/10	$0.6280 $0.6260	▼ −0.32%	▲ +0.01%	$0.6120 (−2.55%)
Apr 14, 2026 8w ago	6-K BULLISH ★ 7/10	$0.7090 $0.7020	▼ −0.99%	▼ −1.76%	$0.6120 (−13.68%)
Apr 9, 2026 9w ago	6-K BULLISH ★ 7/10	$0.7850 $0.7410	▼ −5.61%	▼ −5.54%	$0.6120 (−22.04%)

US Market Status

Market Closed — Opens in 5h 4m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access